Summary Background Australia used the live attenuated herpes zoster vaccine (ZVL, Zostavax®) for 70–79 year-old adults in its National Immunisation Program from 2016. In November 2023 this was replaced with the recombinant adjuvanted herpes zoster vaccine (RZV, Shingrix) and eligibility expanded to include adults ≥65 y...
J. Reekie, Sandrine Stepien, J. Li-Kim-Moy et al.· The Lancet Regional Health -...· 0 citations
Assessment of vaccine effectiveness demonstrated protection against influenza hospitalisation and short-term protection against hospitalisation with COVID-19 in older people.
Hannah Morgan, Dominic E. Dwyer, Mark Holmes et al.· Communicable diseases intell...· 0 citations
Abstract Background Emerging evidence suggests the 4CMenB vaccine provides moderate protection against gonorrhea, likely due to the close genetic relationship between Neisseria gonorrhoeae and Neisseria meningitidis. 4CMenB has an impact on unencapsulated meningococcal oropharyngeal carriage, where outer membrane prote...
Mark McMillan, Bing Wang, Vicki L. Krause et al.· Open Forum Infectious Diseas...· 1 citation
An increased risk of diabetes following SARS-CoV-2 infection during the Omicron dominant period and a protective effect of COVID-19 vaccination is found, however, the findings should be interpreted with caution considering the potential for unmeasured confounding.
Jiahui Qian, Sandrine Stepien, Allen Cheng et al.· International Journal of Pop...· 0 citations
OBJECTIVE
This study estimates Australia's measles susceptibility across all age groups. To our knowledge, this study is the first internationally to combine multiple consecutive serosurvey and population immunisation register data.
METHODS
We estimated age-specific measles susceptibility in 2019 using data from nati...
Zoë Croker, A. McLure, Stephen Lambert et al.· Australian and New Zealand J...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
